Novo Nordisk says Metsera bid won't raise antitrust issues

Core Viewpoint - Novo Nordisk expresses confidence that its proposed acquisition of U.S. drugmaker Metsera will not encounter any antitrust issues [1] Company Summary - Novo Nordisk is pursuing a takeover of Metsera, a U.S. pharmaceutical company [1] - The company believes that the acquisition aligns with regulatory standards and will not face legal challenges related to antitrust laws [1]